Krishnansu S. Tewari

Author

University of California, Irvine Medical Center ORCID

Also Known As

Bookman, Michael A., K S Tewari, K Tewari, K. S. Tewari, K. Tewari, K.S. Tewari, KRISHNANSU S. TEWARI, KRISHNANSU SUJATA TEWARI, KRISHNANSU TEWARI, Krishnansu S Tewari

440

Publications

15K

Citations

H-Index

Concepts

All Affiliations

University of California, Irvine Medical Center University of California, Irvine Roswell Park Comprehensive Cancer Center Creighton University University of Arizona

About

Krishnansu S. Tewari is an author at University of California, Irvine Medical Center specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	77	5K
2	Public Health	14	17	557
3	Health Sciences	11	12	1.1K
4	Nursing	1	1	33
5	Biostatistics	1	1	20

Krishnansu S. Tewari

130

Publications

11.4K

Citations

H-Index

Page 1

	Year	Citations
Improved Survival with Bevacizumab in Advanced Cervical Cancer Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, New England Journal of Medicine	2014	1.5K
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, New England Journal of Medicine	2021	923
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, The Lancet Advanced Cervical CancerCervical Cancer ManagementCervical CancerCervical HealthMedicine	2017	656
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, The Lancet Oncology Paclitaxel–carboplatin ChemotherapySecondary CytoreductionMedicineMetronomic TherapyPharmacology	2017	585
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer Krishnansu S. Tewari, Robert A. Burger, Danielle Enserro, Journal of Clinical Oncology	2019	461
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer Daniela Matei, Virginia L. Filiaci, Marcus E. Randall, New England Journal of Medicine	2019	444
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer Robert L. Coleman, Nick M. Spirtos, Danielle Enserro, New England Journal of Medicine	2019	324
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) David S. Miller, Virginia L. Filiaci, Robert S. Mannel, Journal of Clinical Oncology	2020	313
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn, Gynecologic Oncology Brca2 MutationPhase Ii EvaluationGastrointestinal OncologyMedicineGynecology	2015	262
Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study David S. Miller, Virginia L. Filiaci, Gini F. Fleming, Gynecologic Oncology First Line ChemotherapyMedicineClinical EndpointGynecologyCancer Treatment	2012	249

Page 1